Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 12,657 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Mild to Moderate Asthma
Interventions: fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate; Drug · Other
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more

Conditions: Postherpetic Neuralgia
Interventions: XPF-002, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Jonesboro, Arkansas • Lomita, California • Westlake Village, California + 21 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Compressive Thoracic Lymphatic Pump, Classic Thoracic Lymphatic Pump; Procedure
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham; Other · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Crohn's Disease
Interventions: Placebo, TD-1473; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 39 more

Conditions: Cancer, Health Care Utilization
Interventions: C4 Program; Other
Lead sponsor: Timothy Mullett; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Traumatic Brain Injury
Interventions: Erythropoietin; Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Posttraumatic Stress Disorder
Interventions: DHEA; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Posttraumatic Stress Disorder (PTSD), Anxiety, Depression - Major Depressive Disorder
Interventions: Mindful Self Compassion, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pomona, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay; Drug · Other
Lead sponsor: Razor Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more

Conditions: Obesity, Morbid Obesity, Weight Loss
Interventions: Bariatric Embolization of Arteries with imaging visible Embolics; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus
Interventions: Adult diabetes family-based weight loss intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cognitive Function, Cognitive Performance, Mood
Interventions: BrainJuice Supplement; Dietary Supplement
Lead sponsor: BrainJuice; Industry
Eligibility: 18 Years to 57 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Aging
Interventions: Conventional tDCS, Optimized tDCS, Conventional Sham, Optimized Sham; Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Obesity
Interventions: Financial rewards, Non-Financial rewards; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Kidney Disease
Interventions: darTreg infusion; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pain
Interventions: Goal-Directed Resilience Training; Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neuropathy, Peripheral Neuropathy, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Nicotine Transdermal Patch; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Hypertension
Interventions: Dietitian-Assisted DASH groceries, Self-directed shopping; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Myblu flavor A_2.4, Myblu flavor B_2.4, Myblu flavor C_2.4, Myblu flavor D_2.4, Myblu flavor E_1.2, Myblu flavor F_1.2, Myblu flavor G_2.4, Myblu flavor H_2.4; Other
Lead sponsor: Fontem US LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Alzheimer's Disease, Healthy
Interventions: BMS-708163; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Alzheimer's Disease
Interventions: VI-1121, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more

Conditions: Gut Health, Microbiome, Bloating, Indigestion, Constipation, Diarrhea, Food Cravings, Abdominal Discomfort, Bowel Movement Irregularity
Interventions: Essential Fibre+; Dietary Supplement
Lead sponsor: Artah Nutrition Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

Efficacy and Safety of TD-1473 in Crohn's Disease

Comprehensive Connected Cancer Care (C4): Intervention Evaluation

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI

Neurosteroids in PTSD - Biomarkers to Therapeutics

Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)

Family PALS (PArtners in Lifestyle Support)

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

Optimizing tDCS to Improve Dual Task Gait and Balance

Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance

Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )

Goal-Directed Resilience Training to Mitigate Chronic Pain in Former Football Players

Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension

A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

VI-1121 for the Treatment Alzheimer's Disease

A Clinical Trial to Evaluate the Effects of a Fibre Supplement on Microbiome and Gut Health